Nektar Therapeutics Stock Price, News & Analysis

Nektar Therapeutics (NKTR) and Bristol Myers Squibb (BMY) announced the discontinuation of the global clinical development program for bempegaldesleukin in combination with Opdivo after late-stage studies failed to show clinical benefit in renal cell carcinoma and bladder cancer. In the Phase 3 PIVOT-09 study, bempegaldesleukin did not meet the criteria for statistical significance compared to the TKI control arm. The separate Phase 2 PIVOT-10 study also lacked sufficient efficacy. All related studies will be terminated, allowing patients to pursue standard treatment options.

Nektar Therapeutics (NASDAQ:NKTR) is hosting a conference call for analysts and investors on March 14, 2022, at 5:00 a.m. PST. This follows an update from Bristol-Myers Squibb and Nektar regarding the pivotal Phase 3 PIVOT IO-001 study focused on unresectable or metastatic melanoma. The call will be accessible via Nektar's investor relations website and will be available for replay until April 15, 2022.

Bristol Myers Squibb (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) reported disappointing results from the Phase 3 PIVOT IO-001 study evaluating bempegaldesleukin plus Opdivo versus Opdivo alone in metastatic melanoma. The independent Data Monitoring Committee found no significant benefits in progression-free survival (PFS) or objective response rate (ORR). Consequently, the companies decided to unblind the trial and halt enrollment for the related PIVOT-12 study. The focus will now shift to ongoing studies in renal cell carcinoma and bladder cancer.

Nektar Therapeutics (NKTR) reported its financial results for Q4 and full year 2021, noting cash reserves of approximately $0.8 billion, down from $1.2 billion in 2020. Q4 revenue increased to $25.0 million from $23.5 million year-over-year. However, total annual revenue fell to $101.9 million from $152.9 million, largely due to a $50 million milestone recognized in 2020. The company faced a net loss of $145.6 million in Q4, up from $117.2 million in 2020. Key advances were made in clinical trials, including those for NKTR-358 and NKTR-255, with upcoming topline results expected in H1 2022.

Nektar Therapeutics (NKTR) will release its financial results for Q4 and the year ended December 31, 2021, on February 28, 2022, after U.S. market close. CEO Howard Robin will lead a conference call at 5:00 p.m. ET to discuss the results. Investors can access the live audio webcast through Nektar's website, with replays available until March 28, 2022. The company focuses on R&D in oncology, immunology, and virology, with a pipeline of investigational drugs and partnered medicines.

Nektar Therapeutics (Nasdaq: NKTR) CEO Howard Robin will present at the 40th Annual J.P. Morgan Virtual Healthcare Conference on January 11, 2022, at 3:00 p.m. ET. The event will be accessible via a webcast linked on Nektar's Investor Events Calendar and will remain available for replay until February 11, 2022. Nektar is a biopharmaceutical company based in San Francisco, focusing on R&D in oncology, immunology, and virology.

Nektar Therapeutics (NASDAQ: NKTR) announced promising preliminary results from a Phase 1b proof-of-concept study of NKTR-358, a novel T regulatory cell stimulator, in patients with moderate-to-severe atopic dermatitis. The study showed a dose-dependent reduction in EASI scores, with a 70% maximum reduction at the 24 ug/kg dose after 12 weeks. Sustained disease control was observed for at least 6 months post-treatment. The results suggest NKTR-358's potential to differentiate from current treatments, supporting plans for a Phase 2 study by Eli Lilly.

Exelixis, Inc. has initiated the dose-escalation stage of the STELLAR-002 trial, exploring XL092, a next-generation tyrosine kinase inhibitor, in combination with immuno-oncology therapies for advanced cancers. Collaborating with Bristol-Myers Squibb and Nektar Therapeutics, the trial aims to assess safety and efficacy among patients with advanced solid tumors. The study will focus on renal cell carcinoma, urothelial carcinoma, and metastatic castration-resistant prostate cancer, with primary endpoints including objective response rates and progression-free survival.

Nektar Therapeutics (NASDAQ:NKTR) presented promising data for its investigational drug NKTR-255 at the 63rd American Society of Hematology Annual Meeting. Initial results from a Phase 1 study show NKTR-255 was well tolerated among patients with relapsed/refractory hematologic malignancies, with 53% achieving disease stabilization. The drug demonstrated potential to enhance CAR-T cell persistence and trigger immune response. Ongoing studies aim to investigate NKTR-255 in combination with current therapies for non-Hodgkin's lymphoma and multiple myeloma, with further results anticipated in 2022.